Topological Dissection of Proteomic Changes Linked to the Limbic Stage of Alzheimer's Disease.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 31 07 2021
accepted: 24 09 2021
entrez: 29 10 2021
pubmed: 30 10 2021
medline: 15 1 2022
Statut: epublish

Résumé

Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia worldwide. In AD, neurodegeneration spreads throughout different areas of the central nervous system (CNS) in a gradual and predictable pattern, causing progressive memory decline and cognitive impairment. Deposition of neurofibrillary tangles (NFTs) in specific CNS regions correlates with the severity of AD and constitutes the basis for disease classification into different Braak stages (I-VI). Early clinical symptoms are typically associated with stages III-IV (i.e., limbic stages) when the involvement of the hippocampus begins. Histopathological changes in AD have been linked to brain proteome alterations, including aberrant posttranslational modifications (PTMs) such as the hyperphosphorylation of Tau. Most proteomic studies to date have focused on AD progression across different stages of the disease, by targeting one specific brain area at a time. However, in AD vulnerable regions, stage-specific proteomic alterations, including changes in PTM status occur in parallel and remain poorly characterized. Here, we conducted proteomic, phosphoproteomic, and acetylomic analyses of human postmortem tissue samples from AD (Braak stage III-IV, n=11) and control brains (n=12), covering all anatomical areas affected during the limbic stage of the disease (total hippocampus, CA1, entorhinal and perirhinal cortices). Overall, ~6000 proteins, ~9000 unique phosphopeptides and 221 acetylated peptides were accurately quantified across all tissues. Our results reveal significant proteome changes in AD brains compared to controls. Among others, we have observed the dysregulation of pathways related to the adaptive and innate immune responses, including several altered antimicrobial peptides (AMPs). Notably, some of these changes were restricted to specific anatomical areas, while others altered according to disease progression across the regions studied. Our data highlights the molecular heterogeneity of AD and the relevance of neuroinflammation as a major player in AD pathology. Data are available

Identifiants

pubmed: 34712240
doi: 10.3389/fimmu.2021.750665
pmc: PMC8546208
doi:

Substances chimiques

Antimicrobial Peptides 0
Peptides 0
Proteome 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

750665

Informations de copyright

Copyright © 2021 Velásquez, Szeitz, Gil, Rodriguez, Palkovits, Renner, Hortobágyi, Döme, Nogueira, Marko-Varga, Domont and Rezeli.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Mol Neurodegener. 2020 Jul 16;15(1):40
pubmed: 32677986
Neuroimage. 2013 Jan 1;64:32-42
pubmed: 22960087
Immunol Rev. 2015 Jul;266(1):6-26
pubmed: 26085204
Adv Pharm Bull. 2013;3(2):329-32
pubmed: 24312856
Neurol Clin. 2017 May;35(2):263-281
pubmed: 28410659
Brain Res. 1973 Sep 14;59:449-50
pubmed: 4747772
Nat Med. 2020 May;26(5):769-780
pubmed: 32284590
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
Arch Neurol. 2003 May;60(5):729-36
pubmed: 12756137
Nat Neurosci. 2021 Feb;24(2):276-287
pubmed: 33432193
Alzheimers Dement (N Y). 2020 Nov 02;6(1):e12100
pubmed: 33163614
Front Aging Neurosci. 2019 Dec 10;11:337
pubmed: 31920620
Mol Psychiatry. 2020 Feb;25(2):351-367
pubmed: 31772305
Immunity. 2016 Jan 19;44(1):194-206
pubmed: 26795250
Front Integr Neurosci. 2013 Aug 13;7:59
pubmed: 23964211
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Handb Clin Neurol. 2019;167:231-255
pubmed: 31753135
J Neurotrauma. 2018 Oct 1;35(19):2330-2340
pubmed: 29649924
J Neurosci Res. 2020 Feb;98(2):284-298
pubmed: 30942936
J Biol Chem. 2014 Aug 1;289(31):21326-38
pubmed: 24917678
J Neurochem. 2016 Feb;136(3):457-74
pubmed: 26509334
Alzheimers Dement. 2018 Dec;14(12):1602-1614
pubmed: 30314800
J Biol Chem. 2017 Nov 3;292(44):18129-18144
pubmed: 28893905
Alzheimers Dement (N Y). 2018 Sep 06;4:575-590
pubmed: 30406177
J Neurosci. 2008 Nov 5;28(45):11650-61
pubmed: 18987201
J Exp Med. 2007 Sep 3;204(9):2023-30
pubmed: 17682068
Neuron. 2020 Mar 18;105(6):975-991.e7
pubmed: 31926610
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Neuroscience. 2020 Jun 15;437:161-171
pubmed: 32224230
Brain Behav Immun. 2016 May;54:211-225
pubmed: 26872418
J Neurosci. 2016 May 11;36(19):5185-92
pubmed: 27170117
Front Aging Neurosci. 2019 Mar 19;11:59
pubmed: 30941031
Eur J Immunol. 2012 Nov;42(11):2827-33
pubmed: 23041833
Neuropsychopharmacology. 2021 Jan;46(1):98-115
pubmed: 32898852
Neuroimage. 2009 Oct 1;47(4):1185-95
pubmed: 19447182
Front Pharmacol. 2019 Sep 12;10:1008
pubmed: 31572186
Acta Neuropathol. 2019 Nov;138(5):729-749
pubmed: 31392412
J Chromatogr A. 2002 Mar 8;949(1-2):173-84
pubmed: 11999733
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Cell Physiol Biochem. 2015;37(1):269-75
pubmed: 26302995
Front Immunol. 2021 Apr 01;12:660184
pubmed: 33868310
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Neurobiol Dis. 2019 Oct;130:104509
pubmed: 31207390
Front Immunol. 2020 Mar 31;11:456
pubmed: 32296418
Cell Syst. 2018 Sep 26;7(3):347-350.e1
pubmed: 30172842
Med Sci Monit Basic Res. 2017 Jun 15;23:240-249
pubmed: 28615615
Blood. 2007 Feb 1;109(3):1095-102
pubmed: 17008549
Commun Biol. 2019 Feb 4;2:43
pubmed: 30729181
Mol Neurodegener. 2012 Jul 29;7:36
pubmed: 22838967
J Biomed Sci. 2019 May 9;26(1):33
pubmed: 31072403
Front Genet. 2021 Apr 28;12:633050
pubmed: 33995478
Glia. 2016 Apr;64(4):635-49
pubmed: 26683584
J Neuroimmunol. 2002 Mar;124(1-2):83-92
pubmed: 11958825
J Neuroimmune Pharmacol. 2009 Dec;4(4):399-418
pubmed: 19655259
Curr Med Chem. 2008;15(23):2321-8
pubmed: 18855662
Int J Alzheimers Dis. 2012;2012:369808
pubmed: 22506132
Nature. 2013 Dec 19;504(7480):394-400
pubmed: 24270812
Front Immunol. 2017 Dec 11;8:1805
pubmed: 29312321
Brain Res. 1990 Jul 23;523(2):273-80
pubmed: 2400911
Neurobiol Dis. 2005 Dec;20(3):858-70
pubmed: 15979880
Protein Sci. 2020 Jan;29(1):28-35
pubmed: 31423653
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
J Proteome Res. 2019 Mar 1;18(3):1380-1391
pubmed: 30735395
Mol Neurodegener. 2018 Oct 4;13(1):52
pubmed: 30286791
J Alzheimers Dis. 2017;59(4):1139-1152
pubmed: 28731443
Alzheimers Res Ther. 2020 Jul 6;12(1):80
pubmed: 32631408
Front Immunol. 2018 Mar 02;9:405
pubmed: 29552013
Eur J Immunol. 1999 Jan;29(1):265-76
pubmed: 9933108
Front Cell Neurosci. 2015 Mar 12;9:84
pubmed: 25814934
J Chromatogr B Biomed Sci Appl. 2000 Aug 4;745(1):197-210
pubmed: 10997715

Auteurs

Erika Velásquez (E)

Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden.

Beáta Szeitz (B)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.

Jeovanis Gil (J)

Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden.
Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Jimmy Rodriguez (J)

Division of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.

Miklós Palkovits (M)

Human Brain Tissue Bank, Semmelweis University, Budapest, Hungary.

Éva Renner (É)

Human Brain Tissue Bank, Semmelweis University, Budapest, Hungary.

Tibor Hortobágyi (T)

Institute of Pathology, Faculty of Medicine, University of Szeged, Szeged, Hungary.
ELKH-DE Cerebrovascular and Neurodegenerative Research Group, Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Péter Döme (P)

Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary.

Fábio Cs Nogueira (FC)

Proteomics Unit, Department of Biochemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Laboratory of Proteomics, Laboratório de Apoio ao Desenvolvimento Tecnológico (LADETEC), Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

György Marko-Varga (G)

Division of Clinical Protein Science & Imaging, Department of Biomedical Engineering, Lund University, Lund, Sweden.

Gilberto B Domont (GB)

Proteomics Unit, Department of Biochemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Melinda Rezeli (M)

Division of Clinical Protein Science & Imaging, Department of Biomedical Engineering, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH